| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Executive Chairman
3 companies
Michael G Grey is Director at BMRN, with reported holdings spanning 3 companies. Michael G Grey's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.4M at current prices.
Our model assigns Michael G Grey a below-average insider score of 49/100, based on 7 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -10.0%.
Michael G Grey's largest disclosed position is in BMRN as Director, worth about $2.4M. The BMRN filings lean toward selling, a net 7,500 shares.
Michael G Grey has 41 Form 4 filings on record from June 2016 to August 2026, across 4 companies: Director at OnKure Therapeutics (OKUR), 2021–2026; Director at Mirum Pharmaceuticals (MIRM), 2019–2026; Executive Chairman at Spruce Biosciences (SPRB), 2021–2026, and 1 more.
The 67 reported transactions were 33 option or other derivative awards, 10 option exercises, 9 open-market sales and 6 dispositions back to the company, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 8 sales worth about $13.1M.
The largest open-market sale was 50,000 shares of MIRM at an average $78.00 on December 19, 2025, about $3.9M.
5 of the 6 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other was not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 50,000 | $78.00 | $3,900,000.00 | - | +16.7% | - | |
| Dec 1, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 50,000 | $74.00 | $3,700,000.00 | - | +28.7% | - | |
| Nov 21, 2025 | MIRM Mirum Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 50,000 | $70.00 | $3,500,000.00 | - | +48.6% | - | |
| Sep 14, 2023 | MIRM Mirum Pharmaceuticals, Inc. | Director | Sale+OE | 14,608 | $32.00 | $467,456.00 | - | +4.8% | +27.1% | |
| Jun 8, 2023 | MIRM Mirum Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 14,608 | $29.00 | $423,632.00 | - | -1.9% | -13.7% | |
| May 3, 2023 | MIRM Mirum Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 14,608 | $28.00 | $409,024.00 | - | -12.7% | -10.5% | |
| Mar 5, 2021 | BMRN Biomarin Pharmaceutical Inc | Director | Sale+OE | 5,000 | $76.28 | $381,400.00 | -10.5% | - | - | |
| Aug 3, 2020 | BMRN Biomarin Pharmaceutical Inc | Director | Sale+OE | 2,500 | $120.35 | $300,875.00 | -5.5% | - | - |